Erratum: P16 promoter methylation in Pb2+-exposed individuals (Clinical Toxicology 48:2 124-128) DOI: 10.3109/15563650903567091);P16 promoter methylation in Pb2+-exposed individuals

Clinical Toxicology

Volumn 48, Issue 2, 2010, Pages 124-128

  Leda, Kovatsi ^a   Elisavet, Georgiou ^a   Antrea, Ioannou ^a   Costas, Haitoglou ^a   George, Tzimagiorgis ^a   Helen, Tsoukali ^a   Sofia, Kouidou ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

DNA methylation; Lead; Occupational exposure; P16

Indexed keywords

CYTOSINE; LEAD; PROTEIN P16;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DENATURATION; DNA METHYLATION; HUMAN; LEAD BLOOD LEVEL; LEAD POISONING; MALE; OCCUPATIONAL EXPOSURE; POLYMERASE CHAIN REACTION; PROMOTER REGION;

EID: 77749234090     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.3109/15563650.2010.517385     Document Type: Erratum

References (24)

1. Jarrard DF, Sarkar S, Shi Y, Yeager TR, Magrane G, Kinoshita H, Nassif N, Meisner L, Newton MA, Waldman FM, Reznikoff CA. p16/pRb pathway alterations are required for bypassing senescence in human prostate epithelial cells. Cancer Res 1999; 59:2957-2964.
2. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D, Baylin SB. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995; 55:4525-4530.
3. Basha MR, Wei W, Bakheet SA, Benitez N, Siddiqi HK, Ge YW, Lahiri DK, Zawia NH. The fetal basis of amyloidogenesis: exposure to lead and latent overexpression of amyloid precursor protein and beta-amyloid in the aging brain. J Neurosci 2005; 25(4):823-829.
4. Basha MR, Murali M, Siddiqi HK, Ghosal K, Siddiqi OK, Lashuel HA, Ge YW, Lahiri DK, Zawia NH. Lead (Pb) exposure and its effect on APP proteolysis and Abeta aggregation. FASEB J 2005; 19(14):2083-2084.
5. Wu J, Basha MR, Brock B, Cox DP, Cardozo-Pelaez F, McPherson CA, Harry J, Rice DC, Maloney B, Chen D, Lahiri DK, Zawia NH. Alzheimer's disease (AD)-like pathology in aged monkeys after infantile exposure to environmental metal lead (Pb): evidence for a developmental origin and environmental link for AD. J Neurosci 2008; 28:3-9.
6. Zawia NH, Basha MR. Environmental risk factors and the developmental basis for Alzheimer's disease. Rev Neurosci 2005; 16(4):325-337.
7. White LD, Cory-Slechta DA, Gilbert ME, Tiffany-Castiglioni E, Zawia NH, Virgolini M, Rossi-George A, Lasley SM, Qian YC, Basha MR. New and evolving concepts in the neurotoxicology of lead. Toxicol Appl Pharmacol 2007; 225(1):1-27.
8. Wu J, Basha MR, Zawia NH. The environment, epigenetics and amy-loidogenesis. J Mol Neurosci 2008; 34(1):1-7.
9. Zawia NH, Lahiri DK, Cardozo-Pelaez F. Epigenetics, oxidative stress, and Alzheimer disease. Free Radic Biol Med 2009; 46(9):1241-1249.
10. Lahiri DK, Zawia NH, Greig NH, Sambamurti K, Maloney B. Earlylife events may trigger biochemical pathways for Alzheimer's disease: the "LEARn" model. Biogerontology 2008; 9(6):375-379.
11. Waly M, Olteanu H, Banerjee R, Choi SW, Mason JB, Parker BS, Sukumar S, Shim S, Sharma A, Benzecry JM, Power-Charnitsky VM, Deth RC. Activation of methionine synthase by insulin-like growth factor-1 and dopamine: a target for neurodevelopmental toxins and thimerosal. Mol Psychiatry 2004; 9:358-370.
12. Monteggia LM, Kavalali ET. Rett syndrome and the impact of MeCP2 associated transcriptional mechanisms on neurotransmission. Biol Psychiatry 2009; 65(3):204-210.
13. Baccarelli A, Bollati V. Epigenetics and environmental chemicals. Curr Opin Pediatr 2009; 21(2):243-251.
14. Edwards TM, Myers JP. Environmental exposures and gene regulation in disease etiology. Environ Health Perspect. 2007; 115(9):1264-1270.
15. Salnikow K, Zhitkovich A. Genetic and epigenetic mechanisms in metal carcinogenesis and cocarcinogenesis: nickel, arsenic, and chromium. Chem Res Toxicol 2008; 21:28-44.
16. Chanda S, Dasgupta UB, Guhamazumder D, Gupta M, Chaudhuri U, Lahiri S, Das S, Ghosh N, Chatterjec D. DNA hypermethylation of promoter of gene p53 and p16 in arsenic-exposed people with and without malignancy. Toxicol Sci 2006; 89(2):431-437.
17. Kondo K, Takahashi Y, Hirose T, Nagao T, Tsuyuguchi M, Hashimoto M, Ochiai A, Monden Y, Tangoku A. The reduced expression and aberrant methylation of p16INK4a in chromate workers with lung cancer. Lung Cancer 2006; 53:295-302.
18. Zhang AH, Bin HH, Pan XL, Xi XG. Analysis of p16 gene mutation, deletion and methylation in patients with arseniasis produced by indoor unventilated-stove coal usage in Guizhou, China. J Toxicol Environ Health A 2007; 70(11):970-975.
19. Arendt T, Holzer M, Gärtner U. Neuronal expression of cycline dependent kinase inhibitors of the INK4 family in Alzheimer's disease. J Neural Transm 1998; 105(8-9):949-960.
20. Lüth HJ, Holzer M, Gertz HJ, Arendt T. Aberrant expression of nNOS in pyramidal neurons in Alzheimer's disease is highly co-localized with p21ras and p16INK4a. Brain Res 2000; 852(1):45-55.
21. McShea A, Harris PL, Webster KR, Wahl AF, Smith MA. Abnormal expression of the cell cycle regulators P16 and CDK4 in Alzheimer's disease. Am J Pathol 1997; 150(6):1933-1939.
22. Georgiou E, Valeri R, Tzimagiorgis G, Anzel J, Krikelis D, Tsilikas C, Sarikos G, Destouni C, Dimitriadou A, Kouidou S. Aberrant p16 promoter methylation among Greek lung cancer patients and smokers: Correlation with smoking. Eur J Cancer Prev 2007; 16:396-402.
23. Palmisano WA, Divine KK, Saccomanno G, Gilliand FD, Baylin SB, Herman JG, Belinsky SA. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000; 60:5954-5958.
24. Kibbe WA. OligoCalc: an online oligonucleotide properties calculator. Nucleic Acids Res 2007; 35:43-46.